{"id":"NCT03769168","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)","officialTitle":"An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-07","primaryCompletion":"2024-11-07","completion":"2024-11-07","firstPosted":"2018-12-07","resultsPosted":"2025-05-23","lastUpdate":"2025-05-23"},"enrollment":55,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Psoriatic Arthritis","Enthesitis Related Arthritis"],"interventions":[{"type":"DRUG","name":"Secukinumab","otherNames":["AIN457"]}],"arms":[{"label":"Group 1- Secukinumab 75 mg","type":"EXPERIMENTAL"},{"label":"Group 2 - Secukinumab 150 mg","type":"EXPERIMENTAL"}],"summary":"Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).","primaryOutcome":{"measure":"Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response","timeFrame":"Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.","effectByArm":[{"arm":"Group 1- Secukinumab 75 mg","deltaMin":100,"sd":null},{"arm":"Group 2 - Secukinumab 150 mg","deltaMin":100,"sd":null},{"arm":"Total Secukinumab Dose","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":23,"countries":["United States","Belgium","Germany","Italy","Poland","Russia","South Africa","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Nasopharyngitis","COVID-19","Arthralgia","Pain in extremity","Diarrhoea"]}}